Market Research Logo

Liver Cirrhosis - Pipeline Review, H2 2015

Liver Cirrhosis - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Liver Cirrhosis - Pipeline Review, H2 2015’, provides an overview of the Liver Cirrhosis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Liver Cirrhosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Cirrhosis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Liver Cirrhosis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Liver Cirrhosis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Liver Cirrhosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Liver Cirrhosis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Liver Cirrhosis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Liver Cirrhosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Liver Cirrhosis Overview
Therapeutics Development
Pipeline Products for Liver Cirrhosis - Overview
Pipeline Products for Liver Cirrhosis - Comparative Analysis
Liver Cirrhosis - Therapeutics under Development by Companies
Liver Cirrhosis - Therapeutics under Investigation by Universities/Institutes
Liver Cirrhosis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Liver Cirrhosis - Products under Development by Companies
Liver Cirrhosis - Products under Investigation by Universities/Institutes
Liver Cirrhosis - Companies Involved in Therapeutics Development
Alfa Wassermann S.p.A
Conatus Pharmaceuticals Inc.
Digna Biotech, S.L.
Galectin Therapeutics, Inc.
Gilead Sciences, Inc.
GNI Group Ltd.
Human Stem Cells Institute
Nimbus Therapeutics, LLC
PharmaIN Corporation
Pharmicell Co., Ltd.
S-Evans Biosciences, Inc.
Stelic Institute & Co.
Stempeutics Research Private Limited
Liver Cirrhosis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(sofosbuvir + velpatasvir) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy for Liver Cirrhosis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DB-027 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DB-036 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
emricasan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
F-351 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemacell - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GR-MD-01 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GR-MD-02 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GXHPC-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Livercellgram - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibodies to Antagonize TGF-Beta Receptor Type-1 for HCV associated Liver Cirrhosis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ND-654 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Px-104 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rifaximin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
simtuzumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stem Cell Therapy for Liver Cirrhosis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stem Cell Therapy for Liver Cirrhosis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stem Cell Therapy for Liver Fibrosis and Liver Cirrhosis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stem Cell Therapy for Metabolic, Gastrointestinal and Respiratory Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stem Cell Therapy for Rheumatoid Arthritis and Liver Cirrhosis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stempeucel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
STNM-04 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
thrombopoietin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Undisclosed Peptide for Liver Cirrhosis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Liver Cirrhosis - Recent Pipeline Updates
Liver Cirrhosis - Dormant Projects
Liver Cirrhosis - Discontinued Products
Liver Cirrhosis - Product Development Milestones
Featured News & Press Releases
Jun 25, 2015: Conatus Announces Initial Baseline Data From Phase 2b POLT-HCV-SVR Clinical Trial of Emricasan Confirming Activity of Relevant Mechanisms and Opportunity for Histological Improvement
May 14, 2015: Galectin Therapeutics Reports no Drug-Drug Interaction Between GR-MD-02 and Midazolam
Mar 25, 2015: NICE recommends treatment for brain condition caused by liver failure
Nov 10, 2014: Conatus Pharmaceuticals Presents Late-Breaking Poster At AASLD Annual Meeting
Oct 08, 2014: Conatus Pharmaceuticals Announces Acceptance Of Late-Breaking Abstract For AASLD Annual Meeting
Sep 02, 2014: Conatus Pharmaceuticals Initiates Phase 2 Trial in Patients with Liver Cirrhosis and Separate Open Label Phase 2 Trial in Cirrhosis Patients with Portal Hypertension
Jul 23, 2012: Galectin Therapeutics Receives US Patent for Potential Treatment for Chronic Liver Disease with Fibrosis And Cirrhosis
Jan 20, 2011: Stempeutics Research's Stempeucel LC Recieves DCGI Clearance To Start Phase II Clinical Trial For Liver Cirrhosis
Nov 07, 2007: China Patent and Trademark Office Grants Patent for F351, GNI’s Key Therapeutic Product for Liver Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Liver Cirrhosis, H2 2015
Number of Products under Development for Liver Cirrhosis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Liver Cirrhosis - Pipeline by Alfa Wassermann S.p.A, H2 2015
Liver Cirrhosis - Pipeline by Conatus Pharmaceuticals Inc., H2 2015
Liver Cirrhosis - Pipeline by Digna Biotech, S.L., H2 2015
Liver Cirrhosis - Pipeline by Galectin Therapeutics, Inc., H2 2015
Liver Cirrhosis - Pipeline by Gilead Sciences, Inc., H2 2015
Liver Cirrhosis - Pipeline by GNI Group Ltd., H2 2015
Liver Cirrhosis - Pipeline by Human Stem Cells Institute, H2 2015
Liver Cirrhosis - Pipeline by Nimbus Therapeutics, LLC, H2 2015
Liver Cirrhosis - Pipeline by PharmaIN Corporation, H2 2015
Liver Cirrhosis - Pipeline by Pharmicell Co., Ltd., H2 2015
Liver Cirrhosis - Pipeline by S-Evans Biosciences, Inc., H2 2015
Liver Cirrhosis - Pipeline by Stelic Institute & Co., H2 2015
Liver Cirrhosis - Pipeline by Stempeutics Research Private Limited, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Liver Cirrhosis Therapeutics - Recent Pipeline Updates, H2 2015
Liver Cirrhosis - Dormant Projects, H2 2015
Liver Cirrhosis - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Liver Cirrhosis, H2 2015
Number of Products under Development for Liver Cirrhosis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report